Aleksova, A., Di Nucci, M., Gobbo, M., Bevilacqua, E., Pradella, et al (2015) Factor-V HR2 haplotype and thromboembolic disease. Acta Cardiologica. 70 (6): 707-11. doi: 10.2143/AC.70.6.3120184.

Beitelshees, A.L., Navare, H., Wang, D., Gong, Y., Wessel, J., Moss, J. I., Langaee, T. Y., Cooper-DeHoff, R. M., Sadee, W., Pepine, C. J., Schork, N. J., Johnson, J. A. (2009) CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circulation, Cardiovascular Genetics. 2 (4): 362-70. doi: 10.1161/CIRCGENETICS.109.857839

Blake, C. M., Kharasch, E. D., Schwab, M., Nagele, P. (2013) A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clinical Pharmacology and Therapeutics. 94 (3): 394-9. doi: 10.1038/clpt.2013.96.

Brown, M. and Bussell, J. (2011). Medication Adherence: WHO Cares?. Mayo Clinic Proceedings, 86(4), pp.304-314.

Hamadeh, I. S., Langaee, T. Y., Dwivedi, R., Garcia, S., Burkley, B. M., Chapman, A. B., Johnson, J. A. (2014). Impact of CYP2D6 polymorphisms on clinical efficacy & tolerability of metoprolol tartrate. Clinical Pharmacology and Therapeutics, 96 (2): 175-181.

Bruzelius, M., Sweden, Bottai, M., Sweden, et al (2017) Predicting venous thrombosis in women using a combination of genetic markers and clinical risk factors. Journal of Thrombosis and Haemostasis, 13 (2): 219-227.

Di Stasi, S. L., MacLeod, T. D., Winters, J. D., & Binder-Macleod, S. A. (2010). Effects of Statins on Skeletal Muscle: A Perspective for Physical Therapists. Physical Therapy, 90(10), 1530-1542.

Earle, N., Ingles, J., Bagnall, R. D., Gray, B., Crawford, J., Smith, W., Shelling, A. N., Love, D. R., Semsarian, C. & Skinner, J. R. (2015) NOS1AP Polymorphisms Modify QTc Interval Duration But Not Cardiac Arrest Risk in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 26 (12): 1346-1351.

Gan, G. G., Phipps, M. E., Lee, M. M., Lu, L. S., Subramaniam, R. Y., Bee, P. C. & Chang, S. H. (2011) Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations. Ann Hematol, 90 (6): 635-641.

Hernández-Hernández, R., Sosa-Canache, B., Velasco, M., Armas-Hernandez, M. J., Armas-Padilla, M. C. & Cammarata, R. (2002) Angiotensin II receptor antagonists role in arterial hypertension. Journal of human hypertension, 16 (1): S93.

Johnson, J., Gong, L., Whirl-Carrillo, M., Gage, B., Scott, S., Stein, C., Anderson, J., Kimmel, S., Lee, M., Pirmohamed, M., Wadelius, M., Klein, T. & Altman, R. (2011) Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing. Clinical Pharmacology and Therapeutics, 90 (4): 625-629.

Liggett, S. B., Cresci, S., Kelly, R. J., Syed, F. M., Matkovich, S. J., Hahn, H. S., Diwan, A., Martini, J. S., Sparks, L., Parekh, R. R., Spertus, J. A., Koch, W. J., Kardia, S. L. & Dorn, G. W., 2nd (2008) A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med, 14 (5): 510-517.

Liggett, S. B., Mialet-Perez, J., Thaneemit-Chen, S., Weber, S. A., Greene, S. M., Hodne, D., Nelson, B., Morrison, J., Domanski, M. J., Wagoner, L. E., Abraham, W. T., Anderson, J. L., Carlquist, J. F., Krause-Steinrauf, H. J., Lazzeroni, L. C., Port, J. D., Lavori, P. W. & Bristow, M. R. (2006) A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A, 103 (30): 11288-11293.

Liu, J., Jiang, H. H., Wu, D. K., Zhou, Y. X., Ye, H. M., Li, X., Luo, Z. Y., Guo, Z., Zhang, Y. L., Wang, Y. C., Zhang, W., Zhou, H. H. & Wang, L. S. (2015) Effect of gene polymorphims on the warfarin treatment at initial stage. Pharmacogenomics J, McLean, P. G., Ahluwalia, A. & Perretti, M. (2000) Association between Kinin B1 Receptor Expression and Leukocyte Trafficking across Mouse Mesenteric Postcapillary Venules. J Exp Med, 192 (3): 367-380.

Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E. & Sabatine, M. S. (2009) Cytochrome P-450 Polymorphisms and Response to Clopidogrel. New England Journal of Medicine, 360 (4): 354-362.

Montó, F., Oliver, E., Vicente, D., Rueda, J., Agüero, J., Almenar, L., Ivorra, M. D., Barettino, D. & D''Ocon, P. (2012) Different expression of adrenoceptors and GRKs in the human myocardium depends on heart failure ethiology and correlates to clinical variables. American Journal of Physiology - Heart and Circulatory Physiology, 303 (3): H368.

National Clinical Guidelines Centre (UK) (2011). Stable Angina: Methods, Evidence & Guidance [Internet]. London: Royal College of Physicians (UK); (NICE Clinical Guidelines, No. 126.) 7, Beta blockers vs. calcium channel blockers. Available from:

Ornelas, W. L. H. B. (2008) SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med, 2008 (359): 789-799.

Oscarson, M., Hidestrand, M., Johansson, I. & Ingelman-Sundberg, M. (1997) A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol, 52 (6): 1034-1040.

Pacanowski, M. A., Zineh, I., Li, H., Johnson, B. D., Cooper-DeHoff, R. M., Bittner, V., McNamara, D. M., Sharaf, B. L., Merz, C. N. B., Pepine, C. J. & Johnson, J. A. (2008) Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women''s Ischemia Syndrome Evaluation. Journal of Translational Medicine, 6 11-11.

Pasanen, M. K., Neuvonen, M., Neuvonen, P. J. & Niemi, M. (2006) SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenetics and genomics, 16 (12): 873-879.

Romkes, M., Faletto, M. B., Blaisdell, J. A., Raucy, J. L. & Goldstein, J. A. (1991) Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry, 30 (13): 3247-3255.

Van Noord, C., Aarnoudse, A.-J. L. H. J., Eijgelsheim, M., Sturkenboom, M. C. J. M., Straus, S. M. J. M., Hofman, A., Kors, J. A., Newton-Cheh, C., Witteman, J. C. M. & Stricker, B. H. C. (2009) Calcium channel blockers, NOS1AP, and heart-rate-corrected QT prolongation. Pharmacogenetics and Genomics, 19 (4):

Wieloch, M., Hillarp, A., Strandberg, K., Nilsson, C. & Svensson, P. J. (2009) Comparison and evaluation of a Point-of-care device (CoaguChek XS) to Owren-type prothrombin time assay for monitoring of oral anticoagulant therapy with warfarin. Thrombosis Research, 124 (3): 344-348.

World Health Organization. (2017). ADHERENCE TO LONG-TERM THERAPIES: EVIDENCE FOR ACTION. [online] Available at: [Accessed 8 Aug. 2017].

Follow Us On
Facebook Twitter Instagram LinkedIn YouTube

© 2017 Rightangled LTD. All Rights Reserved.